Fidelity SPDR Advertisement
Home > Boards > Free Zone > Health and Sciences > Biotech Values

If the progression assessments for the two metrics

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 488
Posts 82,074
Boards Moderated 24
Alias Born 09/05/02
160x600 placeholder
Big Homes Can Complicate Retirement
Once you've paid for your house, how much will it cost you?
China Mobile's Need for Speed -- Barron's Asia
Intel Projects More Growth in 2015 -- Update
Zoetis Unveils $500 Million Stock Buyback Plan -- Update
Technip Bids for CGG -- 2nd Update
Appeals Court Grants TV Programmers Stay in FCC Dispute -- Update
Wireless Carriers Bid Up US Airwaves To Record
Two Top-Producing Advisers Leave Merrill Lynch--Street Moves
Chinese Premier Plays Down Qualcomm's Woes
Activision Blizzard to Get $275 Million in Settlement
DewDiligence Member Level  Thursday, 05/24/12 02:22:04 PM
Re: jq1234 post# 142539
Post # of 184126 
If the progression assessments for the two metrics are made on the same schedule for every patient, it shouldn’t be possible for PFS to be greater than TTP. A death in between progression assessments ought not to cause a patient to be deleted from the TTP dataset, but rather for TTP to be censored at the time of death.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist